Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP2 | O95551 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24927663 | 0.98 | FASN (0.37) | FASNPDE10AKMT2ATDP2MEN1 | |
| SCHEMBL24926857 | 0.94 | TDP2 (0.35) | FASNKDM4EATML3MBTL1KMT2A | |
| SCHEMBL24927013 | 0.93 | KMT2A (0.35) | FASNKDM4EATML3MBTL1PDE10A | |
| SCHEMBL24927035 | 0.91 | FASN (0.37) | FASNKMT2ATDP2MEN1DPP4 | |
| SCHEMBL24927474 | 0.91 | KDM4E (0.42) | KDM4EATML3MBTL1PDE10AKMT2A | |
| SCHEMBL24926940 | 0.91 | ALDH1A1 (0.35) | FASNKDM4EATML3MBTL1PDE10A | |
| SCHEMBL24927811 | 0.91 | FASN (0.35) | FASNKMT2AMEN1DPP4CSF1R | |
| SCHEMBL24927665 | 0.89 | FASN (0.35) | FASNKDM4EATML3MBTL1KMT2A | |
| SCHEMBL24830311 | 0.89 | TNKS2 (0.33) | FASNKDM4EATML3MBTL1PDE10A | |
| SCHEMBL26611083 | 0.89 | TNKS2 (0.33) | FASNKDM4EATML3MBTL1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301179-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230301179-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230174560-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174560-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230165130-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230165130-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230034532-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165130-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CYP1A1, CYP2E1, AOX1 | FASN 3893/4885KDM4E 2489/4885ATM 3438/4885 |
| US-20230174560-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CRY1, AOX1, CYP1A1 | FASN 3821/4885KDM4E 3046/4885ATM 3302/4885 |
| US-20230034532-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | NR0B1, CRY1, CCNT1 | FASN 4199/4885KDM4E 4020/4885ATM 1651/4885 |
| US-20230301179-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CRY1, AOX1, CYP1A1 | FASN 3600/4885KDM4E 2808/4885ATM 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.